Version history

{
  "session_id": "sess_SDA-2026-04-16-gap-pubmed-20260410-192526-f2bbb9ab_20260416-135142",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "critique",
  "content": "\n\n# Skeptic's Evaluation of Amyloid Threshold Hypotheses\n\n## Hypothesis 1: PSD-95 Normalization Threshold\n\n### Strongest Weakness: Presumed Causal Mechanism Without Direct Evidence\n\nThe hypothesis invokes PSD-95 (DLG4) stabilization as the mechanistic link between amyloid reduction and cognitive recovery, but the causal chain is underspecified. PSD-95 is a downstream synaptic protein whose expression reflects neuronal health—not a driver of recovery. The critical mechanistic question remains unanswered: *What molecular pathway connects extracellular amyloid clearance to increased postsynaptic PSD-95 protein synthesis or stability?*\n\nWithout this linkage, the hypothesis conflates correlation (synaptic loss correlates with amyloid) with mechanism (amyloid reduction *causes* PSD-95 recovery).\n\n### Counter-Evidence and Complications\n\n- **Alternative解释了 non-linear dose-response**: The TRAILBLAZER-ALZ 2 dose-response may reflect pharmacodynamic saturation or patient selection effects rather than a specific biological threshold. Bimodal therapeutic effects are common in complex biological systems (PMID: 29739473 noted associations, not causation between neurogranin and outcomes).\n\n- **Synaptic biomarkers as surrogate markers**: CSF neurogranin and PSD-95 changes may be epiphenomena of general neuronal health rather than mechanistic drivers. Patients with amyloid reduction but continued neurodegeneration would not fit this model.\n\n- **Temporal assumption unvalidated**: The \"6-month\" prediction window is arbitrary. Synaptic protein turnover rates vary substantially between patients based on baseline neuronal integrity, age, and APOE genotype (PMID: 29030421 examined cross-sectional correlations, not temporal dynamics).\n\n### Pointed Question\n\n**If PSD-95 requires amyloid <20-25 Centiloids for \"stabilization,\" what is the molecular mechanism by which extracellular amyloid plaques (removed from direct synaptic contact) signal intracellularly to regulate postsynaptic protein synthesis? Does this invoke a circulating soluble species (Aβ oligomers, Aβ*56), selective transport dysfunction, or network-level activity changes? The mechanism must connect peripheral amyloid plaques to dendritic protein translation machinery.**\n\n### Confidence Rating: **Weak**\n\n**Rationale**: The hypothesis identifies a legitimate observation (synaptic biomarkers correlate with amyloid burden) but inserts an unspecific protein (PSD-95) as the causal mediator without establishing the signaling pathway. The proposed threshold (20-25 Centiloids) is suspiciously precise given no direct measurements from the source trial. The field lacks direct human evidence linking amyloid PET thresholds to postsynaptic protein stabilization—this would require serial postmortem validation or live synaptic imaging, neither of which exists in TRAILBLAZER-ALZ 2.\n\n---\n\n## Hypothesis 2: TREM2-Dependent Microglial State Transition\n\n### Strongest Weakness: TREM2 Biology Does Not Support a Binary State Transition Model\n\nThe hypothesis implies that TREM2-driven microglia exist in two discrete states (disease-associated vs. homeostatic) separable by a ~30 Centiloid amyloid threshold. This misrepresents current understanding of microglial biology. TREM2-dependent microglia operate on a spectrum, and their function is context-dependent based on ligand (TDP-43, myelin debris, apoptotic neurons, amyloid) rather than amyloid burden alone (PMID: 33355664).\n\n### Counter-Evidence and Complications\n\n- **DAM may be protective, not maladaptive**: Disease-associated microglia in mouse models exhibit amyloid plaque localization and",
  "tokens_used": "904"
}